| abstract |
We have found that IL-6 molecules are useful in inhibiting bone resorption and increasing bone formation. They are thus useful in treating osteoporosis, e.g. acute and/or chronic stages of postmenopausal osteoporosis, including primary and/or secondary osteoporosis and localized osteoporosis, posttraumatic osteoporosis, Paget's disease of bone (osteitis deformans), osteolysis due to bone malignancies, e.g. osteogenic sarcoma, osteodystrophy, e.g. renal osteodystrophy, osteomalacia, multiple myeloma of the bone, osteogenesis imperfecta, hypercalcemia, osteomyelitis, e.g. in conjunction with antibiotics and ectopic calcification. |